Other languages AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Market Closed - Nasdaq Stockholm Other stock markets 11:23:40 2024-05-16 am EDT			5-day change	1st Jan Change
1.785 ^SEK	0.00%		0.00%	-42.60%

May. 14	AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors	CI
Apr. 25	AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors	May. 14
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).	Apr. 09
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024	Apr. 03
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference	Mar. 07
AlzeCure Pharma AB Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's	Mar. 05
AlzeCure Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27
AlzeCure Pharma AB Announces Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators	Feb. 12
AlzeCure Pharma AB Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference	Feb. 06
AlzeCure Pharma AB Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain	Jan. 29
AlzeCure Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
AlzeCure Pharma AB Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD	23-10-25
AlzeCure Pharma AB Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856	23-10-19
Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference	23-10-12
AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference	23-09-26
AlzeCure Pharma AB Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference	23-09-20
AlzeCure Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24
AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's	23-08-09
AlzeCure Pharma AB Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders	23-07-11
AlzeCure Pharma AB Announces New Article on Antidepressive Effects with NeuroRestore ACD856	23-07-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Other languages

Filters